Parenteral and oral pharmacotherapy in prevention of osteoporotic fractures in postmenopausal osteoporosis

被引：1
|
作者：
Pawlak-Bus, Katarzyna [1 ,2 ]
Leszczynski, Piotr [1 ,2 ]
机构：
[1] Wielospecjalisty Szpital J Strusia, Oddzial Reumatol & Osteoporozy, PL-61001 Poznan, Poland
[2] Uniwersytet Med Karola Marcinkowskiego, Klin Reumatol & Rehabil, Pracownia Chorob Metab Kosci & Tkanki Lacznej, Poznan, Poland
来源：
PRZEGLAD MENOPAUZALNY | 2013年 / 12卷 / 03期
关键词：
postmenopausal osteoporosis; fracture prevention; bisphosphonates; denosumab; strontium ranelate; raloxifene; teriparatide;
D O I：
10.5114/pm.2013.36598
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Currently available drugs for the management of postmenopausal osteoporosis can confuse clinicians in daily practice. The number of new oral and therapeutic agents with a different mechanism of action can make a clinical decision to start more complex treatment than previously. This may confirm that in order to know how, when and whom to treat in postmenopausal osteoporosis, specific recommendations based on medical scientific evidence are needed. This manuscript offers compact and easily available information about antiresorptive drugs which can be used by physicians in clinical practice.
引用
收藏
页码：271 / 277
页数：7
相关论文
共 50 条
  • [41] Parenteral Ibandronate in the Therapy of postmenopausal Osteoporosis
    Broell, H.
    Dobnig, H.
    Resch, H.
    Erlacher, L.
    Fahrleitner-Pammer, A.
    Finkenstedt, G.
    Holzer, G.
    Pietschmann, P.
    Pirich, C.
    Wicker, A.
    JOURNAL FUR MINERALSTOFFWECHSEL, 2008, 15 : 2 - 8
  • [42] PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
    LINDSAY, R
    OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 1987, 14 (01) : 63 - 76
  • [43] PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
    STEVENSON, JC
    MACINTYRE, I
    LANCET, 1985, 2 (8450): : 334 - 335
  • [44] PERSISTENCE REGARDING OSTEOPOROSIS TREATMENT IN SECONDARY PREVENTION OF OSTEOPOROTIC FRACTURES IN REHABILITATION CONSULTATION
    Parra Soto, C.
    Garcia Alvarez, E.
    Acosta Rueda, J.
    Espada Zaragoza, R.
    Gonzalez Navarro, E.
    Gonzalez-King Garibotti, C.
    Cuko, G.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S662 - S663
  • [45] Efficacy of oral ibandronate in postmenopausal osteoporosis: Incidence of vertebral fractures by subgroup
    Ettinger, M
    Emkey, R
    Schimmer, R
    Mahoney, P
    Kilbride, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S206 - S207
  • [46] Osteoporotic vertebral fractures in postmenopausal women
    Millard, PS
    Rosen, CJ
    Johnson, KH
    AMERICAN FAMILY PHYSICIAN, 1997, 55 (04) : 1315 - 1322
  • [47] PREVENTION OF NEW OSTEOPOROTIC FRACTURES FOR POSTMENOPAUSAL WOMEN TREATED WITH THE COMBINATION THERAPY (ALENDRONATE WITH ALFACALCIDOL): THE JAPANESE OSTEOPOROSIS INTERVENTION TRIAL (JOINT)-02
    Orimo, H.
    Nakamura, T.
    Ohta, H.
    Fukunaga, M.
    Hosoi, T.
    Uemura, Y.
    Ohashi, Y.
    Shiraki, M.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : S757 - S757
  • [48] The cost-effectiveness of calcium and vitamin D or hormone replacement therapy in the prevention of osteoporosis and osteoporotic fractures in Canadian postmenopausal women.
    Papadimitropoulos, EA
    Goeree, R
    Blackhouse, G
    Coyte, P
    Josse, RG
    Adachi, J
    Greenwood, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S384 - S384
  • [49] Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis
    Brandi, M-L
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (11) : 2553 - 2563
  • [50] RISK FACTORS OF OSTEOPOROSIS AND OSTEOPOROTIC FRACTURES
    Sepici, V.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (SUPPL 1) : S122 - S123
12345